Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Nonprescription Drugs and Arthritis Advisory Committees to meet jointly July 15.

This article was originally published in The Tan Sheet

Executive Summary

NONPRESCRIPTION DRUGS AND ARTHRITIS ADVISORY COMMITTEES JOINT MEETING is scheduled for July 15. The possibility of treating migraines in the OTC setting is slated as the topic for discussion. One candidate for the new OTC indication is said to be Bristol-Myers Squibb's established nonprescription analgesic Excedrin Extra Strength, which contains acetaminophen 250 mg, aspirin 250 mg and caffeine 65 mg per dose.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087122

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel